J591

PSMA-targeted monoclonal antibody · BZL Biologics

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for J591, covering 2007-01-22 to 2007-01-22. Get the full timeline:

Most recent: Clinical Trial Update: Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2 [Phase 2]